Replimune Group, Inc.(REPL)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
REPL Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Replimune Group, Inc. (REPL), a Healthcare sector company. REPL is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q4 2026), Replimune Group, Inc. reports net income of $-73.2M, free cash flow of $-56.2M. Top institutional holders of REPL by reported 13-F value include BAKER BROS. ADVISORS, RTW INVESTMENTS,, BlackRock,, based on the most recent SEC filings. REPL trades on the Nasdaq exchange and files with the SEC under CIK 1737953. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate REPL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Replimune Group, Inc. directly from SEC EDGAR.
Net Income
Q4 2026
$-73.2M
Free Cash Flow
Q4 2026
$-56.2M
Get alerted when REPL's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Replimune Group, Inc. including:
Top Institutional Holders of REPL
BAKER BROS. ADVISORS LP
$84.5M11,045,336 shRTW INVESTMENTS, LP
$56.3M7,356,916 shBlackRock, Inc.
$47.7M6,239,239 shSUVRETTA CAPITAL MANAGEMENT, LLC
$32.3M4,221,836 shSTATE STREET CORP
$28.9M3,782,237 shFCPM III SERVICES B.V.
$21.5M2,808,368 shVANGUARD CAPITAL MANAGEMENT LLC
$21.1M2,759,120 shD. E. Shaw & Co., Inc.
$17.9M2,336,528 shGOLDMAN SACHS GROUP INC
$17.4M2,277,276 shFMR LLC
$15.6M2,045,490 sh
| Fund | Value | Shares |
|---|---|---|
| BAKER BROS. ADVISORS LP | $84.5M | 11,045,336 |
| RTW INVESTMENTS, LP | $56.3M | 7,356,916 |
| BlackRock, Inc. | $47.7M | 6,239,239 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | $32.3M | 4,221,836 |
| STATE STREET CORP | $28.9M | 3,782,237 |
| FCPM III SERVICES B.V. | $21.5M | 2,808,368 |
| VANGUARD CAPITAL MANAGEMENT LLC | $21.1M | 2,759,120 |
| D. E. Shaw & Co., Inc. | $17.9M | 2,336,528 |
| GOLDMAN SACHS GROUP INC | $17.4M | 2,277,276 |
| FMR LLC | $15.6M | 2,045,490 |
More Healthcare Companies
View all Healthcare →Put REPL on your watchlist
Track score changes the day Replimune Group, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is REPL a good stock to buy?
13F Pro's AI-powered analysis of Replimune Group, Inc. (REPL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for REPL are available on the REPL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own REPL?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling REPL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Replimune Group, Inc.'s investment landscape.